What is HC Wainwright’s Estimate for ACAD FY2026 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will earn $0.56 per share for the year, up from their previous estimate of $0.37. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.40 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.95 EPS, FY2029 earnings at $3.28 EPS and FY2030 earnings at $3.42 EPS.

ACAD has been the subject of several other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Oppenheimer upped their target price on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the stock a “market perform” rating in a report on Wednesday. Stifel Nicolaus increased their target price on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 21st. Finally, Bank of America reissued a “buy” rating and set a $14.50 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.44.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $28.45 on Friday. The stock’s fifty day simple moving average is $24.24 and its 200 day simple moving average is $23.23. ACADIA Pharmaceuticals has a one year low of $19.69 and a one year high of $29.48. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of 12.82, a P/E/G ratio of 19.47 and a beta of 0.81.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $308.00 million during the quarter, compared to analysts’ expectations of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 EPS.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its position in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth about $26,000. Transamerica Financial Advisors LLC lifted its position in shares of ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 1,005 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $52,000. Institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. This represents a 46.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 26.20% of the company’s stock.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA beat second-quarter earnings and revenue estimates, driven by strong sales of Daybue and Nuplazid. The company also raised its 2026 revenue outlook, providing evidence of continued commercial momentum. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Citizens JMP raised its price target from $35 to $36 and maintained a “market outperform” rating, implying additional upside from the stock’s referenced price level. Citizens JMP Raises ACADIA Price Target
• Positive Sentiment: Rising earnings estimates are providing another potential catalyst. Zacks said recent estimate revisions indicate ACADIA’s shares could continue moving higher, while HC Wainwright raised its Q3 2026 EPS forecast to $0.15 from $0.13 and its FY2027 forecast to $1.89 from $1.70. Can Acadia Run Higher on Rising Earnings Estimates?
• Neutral Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate to $0.20 from $0.21 but retained a “Hold” rating. The mixed revisions suggest improving longer-term expectations but limited near-term conviction. HC Wainwright ACADIA Estimates
• Positive Sentiment: Recent earnings-call materials and coverage highlighted the second-quarter results and product performance, reinforcing the market’s focus on ACADIA’s revenue growth and profitability trajectory. ACADIA Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.